These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 10952787

  • 1. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide.
    Parkins CS, Holder AL, Hill SA, Chaplin DJ, Tozer GM.
    Br J Cancer; 2000 Sep; 83(6):811-6. PubMed ID: 10952787
    [Abstract] [Full Text] [Related]

  • 2. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
    Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, Barber PR, Vojnovic B, Chaplin DJ.
    Cancer Res; 2001 Sep 01; 61(17):6413-22. PubMed ID: 11522635
    [Abstract] [Full Text] [Related]

  • 3. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.
    Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ.
    Cancer Res; 1999 Apr 01; 59(7):1626-34. PubMed ID: 10197639
    [Abstract] [Full Text] [Related]

  • 4. The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro.
    Brooks AC, Kanthou C, Cook IH, Tozer GM, Barber PR, Vojnovic B, Nash GB, Parkins CS.
    Anticancer Res; 2003 Apr 01; 23(4):3199-206. PubMed ID: 12926054
    [Abstract] [Full Text] [Related]

  • 5. Ischemia reperfusion injury in tumors: the role of oxygen radicals and nitric oxide.
    Parkins CS, Dennis MF, Stratford MR, Hill SA, Chaplin DJ.
    Cancer Res; 1995 Dec 15; 55(24):6026-9. PubMed ID: 8521386
    [Abstract] [Full Text] [Related]

  • 6. Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses.
    Tozer GM, Prise VE, Lewis G, Xie S, Wilson I, Hill SA.
    Clin Cancer Res; 2009 Jun 01; 15(11):3781-90. PubMed ID: 19470729
    [Abstract] [Full Text] [Related]

  • 7. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.
    Holwell SE, Cooper PA, Grosios K, Lippert JW, Pettit GR, Shnyder SD, Bibby MC.
    Anticancer Res; 2002 Jun 01; 22(2A):707-11. PubMed ID: 12017147
    [Abstract] [Full Text] [Related]

  • 8. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503.
    Hill SA, Toze GM, Pettit GR, Chaplin DJ.
    Anticancer Res; 2002 Jun 01; 22(3):1453-8. PubMed ID: 12168822
    [Abstract] [Full Text] [Related]

  • 9. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.
    Holwell SE, Cooper PA, Thompson MJ, Pettit GR, Lippert LW, Martin SW, Bibby MC.
    Anticancer Res; 2002 Jun 01; 22(6C):3933-40. PubMed ID: 12553015
    [Abstract] [Full Text] [Related]

  • 10. Peroxynitrite is an important mediator in thermal injury-induced lung damage.
    Chen LW, Wang JS, Chen HL, Chen JS, Hsu CM.
    Crit Care Med; 2003 Aug 01; 31(8):2170-7. PubMed ID: 12973176
    [Abstract] [Full Text] [Related]

  • 11. Pretreatment with Tongxinluo protects porcine myocardium from ischaemia/reperfusion injury through a nitric oxide related mechanism.
    Cheng YT, Yang YJ, Zhang HT, Qian HY, Zhao JL, Meng XM, Luo FL, Wu YL.
    Chin Med J (Engl); 2009 Jul 05; 122(13):1529-38. PubMed ID: 19719943
    [Abstract] [Full Text] [Related]

  • 12. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.
    Chaplin DJ, Pettit GR, Hill SA.
    Anticancer Res; 1999 Jul 05; 19(1A):189-95. PubMed ID: 10226542
    [Abstract] [Full Text] [Related]

  • 13. [The protective efficacy of rabbit endogenous nitric oxide against acute rabbit lung ischemia-reperfusion injury and its mechanism].
    Liang GY, Niu YM, Liu DX, Xu G, Cai QY.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar 05; 36(2):246-8, 280. PubMed ID: 15807279
    [Abstract] [Full Text] [Related]

  • 14. Burn-induced lung damage in rat is mediated by a nitric oxide/cGMP system.
    Chen LW, Hwang YC, Chen CJ, Wang JS, Chen JS, Hsu CM.
    Shock; 2003 Oct 05; 20(4):369-74. PubMed ID: 14501952
    [Abstract] [Full Text] [Related]

  • 15. Intrathecally injected morphine inhibits inflammatory paw edema: the involvement of nitric oxide and cyclic-guanosine monophosphate.
    Brock SC, Tonussi CR.
    Anesth Analg; 2008 Mar 05; 106(3):965-71, table of contents. PubMed ID: 18292447
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4.
    Griggs J, Skepper JN, Smith GA, Brindle KM, Metcalfe JC, Hesketh R.
    Am J Pathol; 2002 Mar 05; 160(3):1097-103. PubMed ID: 11891206
    [Abstract] [Full Text] [Related]

  • 17. Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126.
    Cullis ER, Kalber TL, Ashton SE, Cartwright JE, Griffiths JR, Ryan AJ, Robinson SP.
    Microvasc Res; 2006 Mar 05; 71(2):76-84. PubMed ID: 16530791
    [Abstract] [Full Text] [Related]

  • 18. Tumour-derived and host-derived nitric oxide differentially regulate breast carcinoma metastasis to the lungs.
    Gauthier N, Lohm S, Touzery C, Chantôme A, Perette B, Reveneau S, Brunotte F, Juillerat-Jeanneret L, Jeannin JF.
    Carcinogenesis; 2004 Sep 05; 25(9):1559-65. PubMed ID: 15059928
    [Abstract] [Full Text] [Related]

  • 19. Statins inhibit neutrophil infiltration in skeletal muscle reperfusion injury.
    Cowled PA, Khanna A, Laws PE, Field JB, Varelias A, Fitridge RA.
    J Surg Res; 2007 Aug 05; 141(2):267-76. PubMed ID: 17559881
    [Abstract] [Full Text] [Related]

  • 20. Ghrelin-induced gastroprotection against ischemia-reperfusion injury involves an activation of sensory afferent nerves and hyperemia mediated by nitric oxide.
    Konturek PC, Brzozowski T, Walter B, Burnat G, Hess T, Hahn EG, Konturek SJ.
    Eur J Pharmacol; 2006 Apr 24; 536(1-2):171-81. PubMed ID: 16581065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.